2025 Latin America Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 Latin America Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antisense and RNAi Therapeutics Market in Latin America include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, and Novartis AG. Alnylam Pharmaceuticals is a leader in RNAi therapeutics with a strategy to develop RNAi treatments for major tissues and has significant partnerships like the one with Roche to co-develop and commercialize RNAi drugs globally, including Latin America. Ionis Pharmaceuticals pioneers antisense technology with several FDA-approved drugs targeting neurological and rare diseases and is expanding its market presence through strategic collaborations. Sarepta Therapeutics focuses on RNA-based therapies targeting rare genetic disorders and is recognized globally for innovation in this space. Novartis AG gained FDA approval for Leqvio, an siRNA therapy, reflecting its active role in RNAi therapeutics and its interest in markets worldwide.
In Latin America, these companies benefit from a rapidly growing market driven by increasing revenues and rising demand for RNA interference therapies, particularly in Brazil, which shows the highest growth forecast at a CAGR of over 17% and leads in regional revenues. Other global players like GSK and Sanofi are also competitors in the Latin American market but the four mentioned companies are noted for their substantial investment and clinical activities relating to antisense and RNAi therapeutics in this region. The Latin America market, forecasted to reach over USD 230 million by 2030, is part of a global trend in expanding RNA-based therapeutic applications for neurodegenerative, genetic, and cardiometabolic diseases.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antisense and RNAi Therapeutics Market in Latin America include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, and Novartis AG. Alnylam Pharmaceuticals is a leader in RNAi therapeutics with a strategy to develop RNAi treatments for major tissues and has significant partnerships like the one with Roche to co-develop and commercialize RNAi drugs globally, including Latin America. Ionis Pharmaceuticals pioneers antisense technology with several FDA-approved drugs targeting neurological and rare diseases and is expanding its market presence through strategic collaborations. Sarepta Therapeutics focuses on RNA-based therapies targeting rare genetic disorders and is recognized globally for innovation in this space. Novartis AG gained FDA approval for Leqvio, an siRNA therapy, reflecting its active role in RNAi therapeutics and its interest in markets worldwide.
In Latin America, these companies benefit from a rapidly growing market driven by increasing revenues and rising demand for RNA interference therapies, particularly in Brazil, which shows the highest growth forecast at a CAGR of over 17% and leads in regional revenues. Other global players like GSK and Sanofi are also competitors in the Latin American market but the four mentioned companies are noted for their substantial investment and clinical activities relating to antisense and RNAi therapeutics in this region. The Latin America market, forecasted to reach over USD 230 million by 2030, is part of a global trend in expanding RNA-based therapeutic applications for neurodegenerative, genetic, and cardiometabolic diseases.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
